Implantable Sensor Market Scope And Analysis

Report Code : TIPRE00016982
Category : Life Sciences

No. of Pages : 150

Buy Now

Implantable Sensor Market Analysis, Scope, and Growth by 2031

Buy Now

Implantable Sensor Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 4.19 billion
Market Size by 2031	US$ 17.32 billion
Global CAGR (2023 - 2031)	11.1%
Historical Data	2021-2022
Forecast period	2023-2031
Segments Covered	By Type Glucose Sensor Temperature Sensor Oxygen Sensor Pressure Sensor By Application Medical Diagnostic Clinical Therapy Personal Healthcare Imaging By End User Hospitals Clinics Diagnostic Centre
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Analog Devices Inc DEXCOM INC Glusense Ltd Honeywell International Inc Medtronic NXP SEMICONDUCTORS N V Pinnacle Technology Inc Sensirion AG TE Connectivity Texas Instruments Incorporated

Implantable Sensor Market News and Recent Developments

The Implantable Sensor Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for implantable sensors and strategies:

In December 2023, Medstar became the first company in the world to implant Cordella sensor implant for advanced heart failure. The sensor remotely sends the patient’s pulmonary artery pressure via a wireless microelectromechanical sensor to the team of doctors. With this real-time data, doctors can proactively adjust medications and therapies with the goal of reducing HF hospitalizations. (Source: MedStar Health, Press Release, 2024)
In Feb 2022, Ascensia Diabetes Care, a global diabetes care company, announced that its partner Senseonics Holdings, Inc. has received approval from the US Food and Drug Administration (FDA) for the next-generation Eversense® E3 Continuous Glucose Monitoring (CGM) System. Ascensia plans to make the Eversense E3 sensor, which can be used for up to 6 months, available to patients in the US (Source: Ascensia Diabetes Care Holdings AG., Senseonics, Inc. Press Release/Company Website/Newsletter, 2024)

Implantable Sensor Market Report Coverage and Deliverables

The “Implantable Sensor Market Size and Forecast (2024–2031)” report provides a detailed analysis of the market covering below areas:

Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Market dynamics such as drivers, restraints, and key opportunities
Key future trends
Detailed PEST/Porter’s Five Forces and SWOT analysis
Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
Detailed company profiles